Condition: Generalized Myasthenia Gravis · Sponsor: Novartis Pharmaceuticals
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Honor Health Research Institute | Scottsdale, Arizona, United States | Recruiting |
| Fullerton Neuro and Headache Ctr | Fullerton, California, United States | Recruiting |
| SC3 Research Pasadena | Pasadena, California, United States | Recruiting |
| California Pacific Medical Center | Sacramento, California, United States | Recruiting |
| Neurology Offices Of South Florida | Boca Raton, Florida, United States | Withdrawn |
| Superior Associates in Research LLC | Hialeah, Florida, United States | Withdrawn |
| Augusta University Georgia | Augusta, Georgia, United States | Recruiting |
| Hawaii Pacific Neuroscience LLC | Honolulu, Hawaii, United States | Withdrawn |
| University of Chicago Medical Centr | Chicago, Illinois, United States | Recruiting |
| Prairie Heart Institute | Springfield, Illinois, United States | Recruiting |
| Mid Atlantic Epilepsy and Sleep Ctr | Bethesda, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
+ 113 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06517758